Danaher Corporation (DHR)
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How to Invest in AI Drug Discovery
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
ELV or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
ELV or DHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
